Company facts
- Headquarters
- San Diego, California
- Most recent report
- 10-Q, filed Aug 6, 2026
- Incorporated
- Delaware
- Filings on record
- 191 filings
- On EDGAR
- CIK 1817241
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company Emerging growth company
Financials 8 of 10
News 8 of 20
Prospectuses and Registrations 8 of 15
- S-3 Shelf registration statement Aug 6, 2026
- 424B5 Prospectus supplement for an offering May 8, 2026
- FWP Free writing prospectus May 8, 2026
- S-8 Registration statement for an employee plan Mar 10, 2026
- S-3 Shelf registration statement Aug 6, 2025
- S-8 Registration statement for an employee plan Aug 6, 2025
- S-8 Registration statement for an employee plan Jul 22, 2024
- 424B4 Final prospectus for an offering Jul 22, 2024
Proxies 3
Ownership 8 of 118
- 4 Insider reported a trade Aug 19, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 10, 2026
- 4 Insider reported a trade Jul 31, 2026
- 4 Insider reported a trade Jul 28, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Jul 23, 2026
- 4 Insider reported a trade Jul 23, 2026
Other 8 of 25
- EFFECT Notice that a registration became effective Aug 14, 2026
- ARS Annual report sent to shareholders Aug 3, 2026
- EFFECT Notice that a registration became effective Aug 15, 2025
- CORRESP Reply to SEC staff Aug 13, 2025
- UPLOAD Comment letter from SEC staff Aug 11, 2025
- ARS Annual report sent to shareholders Apr 29, 2025
- SEC STAFF LETTER Jul 19, 2024
- EFFECT Notice that a registration became effective Jul 18, 2024
Everything here comes from Artiva Biotherapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.